Specifications
- Purity
- ≥97% (HPLC)
- Appearance
- White to light yellow powder
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (10 mg/ml), DMF (10 mg/ml), water (10 mg/ml)
- Melting Point
- 267 °C (dec.) (lit.)
Category: Antibiotics
Vinblastine sulfate is a vinca alkaloid and a chemical analog of vincristine. It is an anticancer agent with anti-mitotic properties and immunosuppressive activity. Vinblastine sulfate depolymerizes microtubules by binding tubulin and inducing self-association in spiral aggregates. This reaction that appears to be regulated by the C-terminus of β-tubulin and is enhanced by GDP and GTP. Vinblastine sulfate has been observed to arrest the cell cycle in the G2/M-phase by blocking mitotic spindle formation. Vinblastine sulfate has also been documented to trigger Raf-1 activation and phosphorylation of Bcl-2 family proteins, to induce p53 expression, and to induce apoptosis in several tumor cell lines. Shown to inhibit autophagosome maturation.
Synonyms | VLB, Vincaleukoblastine sulfate salt, NSC 49842 |
---|---|
Purity | ≥97% (HPLC) |
Appearance | White to light yellow powder |
CAS-Number | 143-67-9 |
Molecular Formula | C46H58N4O9 . H2SO4 |
Molecular Weight | 909.05 |
Identity | 1H-NMR |
Solvents | DMSO (10 mg/ml), DMF (10 mg/ml), water (10 mg/ml) |
Melting Point | 267 °C (dec.) (lit.) |
Smiles | O=S(O)(O)=O.O[C@@]1(C(OC)=O)[C@]2([H])N(C)C3=C(C=C([C@@](C(OC)=O)(C[C@@H](C[C@]4(CC)O)C[N@@](C4)CC5)C6=C5C(C=CC=C7)=C7N6)C(OC)=C3)[C@]28[C@@]([C@](C=CC9)(CC)[C@H]1OC(C)=O)([H])N9CC8 |
InChi Key | KDQAABAKXDWYSZ-JKDPCDLQSA-N |
Shipping | AMBIENT |
Short Term Storage | RT |
Long Term Storage | +4°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Hazard statements | H302-H315-H318-H335 |
Precautionary statements | P280-P301 + P312 + P330-P304 + P340 + P312-P305 + P351 + P338 + P310 |
GHS Symbol | GHS05+GHS07 |
Signal word | Danger |
Transportation | Not dangerous goods |
References | (1) M.A. Jordan, et al., Cancer Res. 45, 2741 (1985), (2) R.H. Himes, Pharmacol. Ther. 51, 257 (1991), (3) K. Tsukidate, et al., Am. J. Pathol. 143, 918 (1993), (4) D. Panda, et al., J. Biol. Chem. 271, 29807 (1996), (5) S.S. Rai & J. Wolf, J. Biol. Chem. 273, 31131 (1998), (6) E. Tashiro, et al., Jpn. J. Cancer Res. 89, 940 (1998), (7) A. Jordan, et al., Med. Res. Rev. 18, 259 (1998), (8) M.A. Jordan & L. Wilson, Meth. Enzymol. 298, 252 (1998), (9) S.S. Rai, et al., PNAS 95, 4253 (1998), (10) G.K. Chen, et al., Br. J. Cancer. 83, 892 (2000), (11) R.A. Veldhoen, et al., Oncogene 32, 736 (2012), (12) P. Keglevich, et al., Molecules 17, 5893 (2012) (Review) |
InChi | InChI=1S/C46H58N4O9.H2O4S/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7,1-5(2,3)4/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3,(H2,1,2,3,4)/t28-,37+,38-,39-,42+,43-,44-,45+,46+,/m1./s1 |
Quantity | 25 mg, 50 mg, Bulk |